CD20 positive

P1/2, N=12, Active, not recruiting, Washington University School of Medicine | Recruiting --> Active, not recruiting

P2, N=40, Recruiting, French Innovative Leukemia Organisation | Trial completion date: Mar 2027 --> Sep 2029 | Trial primary completion date: Mar 2026 --> Mar 2028

P1, N=18, Not yet recruiting, M.D. Anderson Cancer Center

P1, N=16, Completed, Acepodia Biotech, Inc. | Active, not recruiting --> Completed | N=42 --> 16 | Trial completion date: Sep 2027 --> Mar 2026 | Trial primary completion date: Jul 2026 --> Mar 2026

Due to the diagnostic complexity, he was treated as having a non-Hodgkin lymphoma-like entity with R-CHOP chemotherapy (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) Although UCD is typically considered curable with surgical resection, this case demonstrates that, in rare cases, it can progress to lymphoma, specifically NLPHL. This case illustrates that even localized forms of UCD may be associated with subsequent lymphoid malignancy, emphasizing the importance of continuous clinical surveillance and a multidisciplinary approach to management. Histopathological reassessment of new lesions is crucial, and clinicians should consider the possibility of malignant transformation in patients with a history of UCD to ensure accurate diagnosis and timely treatment.

Although uncommon, primary cardiac lymphoma should be considered in patients with unexplained SVC syndrome, particularly when anticoagulation fails or imaging demonstrates right atrial involvement. Early tissue diagnosis is essential, as prompt initiation of chemotherapy may improve outcomes in this aggressive yet potentially treatable malignancy.

In conclusion, tumor-derived CD20-positive EVlarge represent a novel mechanism of rituximab resistance by reducing effective antibody exposure and impairing immune-mediated cytotoxicity. Circulating CD20-positive EVlarge provide a biologically informative biomarker that predicts clinical outcomes independently of established prognostic factors and may guide optimization of antibody-based therapy in DLBCL.

She underwent therapy with rituximab, methotrexate, procarbazine, and vincristine followed by high-dose cytarabine, achieving temporary remission; however, relapse occurred 1 month after consolidation therapy. This case also suggests a potential therapeutic role for tirabrutinib in early-relapsing LC. https://thejns.org/doi/10.3171/CASE26337.

Thus, MAFB overexpression promoted diabetic foot ulcer healing by fostering a tissue repair phenotype and suppressing inflammation and oxidative stress through the transcriptional activation of WDR74. These findings underscore the potential of MAFB as a therapeutic target for improving diabetic wound healing, which could lead to novel clinical strategies for treating DFUs.

Our findings support the existence of a subset of extranodal follicular lymphomas lacking an IGH::BCL2 rearrangement and highlight alternative pathways of lymphomagenesis with implications for classification and diagnosis. The identification of biallelic CREBBP mutations and a FOXO1 mutation provides molecular insight into extranodal FL biology, suggesting an overlap with nodal FL while supporting alternative oncogenic pathways in extranodal disease.

When miscellaneous pathogens bearing fucose-containing carbohydrate antigens happened to invade the dermis through minor injuries, DC-SIGN, a pattern recognition receptor, and TLR4 on macrophages may have modulated Th differentiation into Th27/Th2 to generate follicular helper T cells and GC to induce humoral immunity. Accumulation of reports is required to check the validity of this speculation.

Pediatric gliomas and GNTs frequently express CAIX and monocyte/macrophage-related biomarkers but exhibit a low immune checkpoint profile (PD-1 and PD-L1). Unlike findings from adult studies, CAIX was neither enriched in HGGs nor associated with a worse prognosis. Strong CD68 expression may represent a candidate target for combination therapeutic strategies, although validation in a larger, homogeneous pediatric CNS tumor cohort is needed.